Key Takeaways
- Reimbursement dictates clinical practice: Administrators describe the dynamic with a rueful shorthand (“You do what you get paid for”) that captures the gap between what research recommends and what payers will cover in behavioral health.
- Prior authorization blocks newer, more effective medications: Neicole Knott, Vice President of Operations at NewVista Behavioral Health, said providers go through an arduous prior authorization process for newer medications with stronger efficacy data, while older, less effective drugs remain the only option for many patients.
- Cognitive behavioral therapy is the default because it is reliably reimbursed: Knott estimated CBT works for roughly 25% of her patient population, but it remains the dominant modality because other evidence-based practices that would work in combination with medications go unfunded.
- Medication-assisted treatment remains underutilized: Research consistently shows that MAT (including buprenorphine and methadone paired with counseling) produces significantly better outcomes than abstinence-only approaches, yet philosophical resistance and uneven reimbursement keep MAT underused in settings where it could save lives.
- Telehealth and Medicaid expansion have eased MAT barriers, unevenly: Medicare removed geographic restrictions for telehealth-based substance use treatment and many states expanded Medicaid MAT coverage, but the resulting patchwork still leaves providers navigating barriers patient-by-patient.
No provider fully escapes the constraint: Knott said any operator claiming to be unconstrained by reimbursement is probably not looking at their entire system, since experimental programs rarely pay for themselves. - CCBHCs offer a glimpse of what aligned payment can do: Clinics that adopted the Certified Community Behavioral Health Clinic model hired an average of 27 new positions and grew their workforce by 16%, because the payment structure accounts for staffing needs and actual costs of care delivery.
- The path forward is payment alignment, not provider exhortation: Until reimbursement structures reflect clinical evidence, behavioral health practice will continue to trail behavioral health science, and the shorthand will remain uncomfortably accurate.
There is a phrase that circulates among behavioral health administrators, a kind of rueful shorthand for the gap between what research recommends and what practice delivers: “You do what you get paid for.” It is not a philosophy anyone endorses with enthusiasm. It is simply a description of how the economics work.
“Whether you’re for-profit or non-profit, you’re a business,” said Neicole Knott, Vice President of Operations at NewVista Behavioral Health. “You still have to have oxygen to breathe, and that oxygen is reimbursement.”
The result is an industry in which clinical practice often lags years behind the evidence. Newer medications with demonstrated superior efficacy get caught in prior authorization limbo while older, less effective drugs remain readily available. Therapeutic interventions that outperform cognitive behavioral therapy for certain populations go unfunded because payers have not updated their coverage guidelines. Providers who seek to offer state-of-the-art care are constrained by reimbursement structures that have not kept pace with the science they are expected to support. The broader reality check on value-based care in mental health and SUD makes clear why payment reform at scale has been harder to execute than to propose.
The Gap Between Behavioral Health Research and Reimbursement Revenue
Friction manifests in mundane ways that accumulate into significant obstacles. Knott pointed to medication as one example. “We go through an arduous process of prior authorizations for new medications that have more efficacy or research behind them than old medications do. But, sometimes, patients only have old medications available to them.”
The same dynamic shapes therapeutic approaches. Cognitive behavioral therapy (CBT) has become close to a default treatment modality, not because it works for everyone (Knott estimated it helps about a quarter of her patient population) but because it is what payers will reliably cover. “Although the CBT model works for about 25% of our patients, there are other evidence-based practices that work in conjunction oftentimes with medications that go unfunded,” she said. Operators trying to introduce new approaches often find themselves squeezed into narrow spaces, as in Catalight’s partnership with AI startup Frontera to scale a lower-intensity care model, where clinical innovation has to fit within the reimbursement envelope in order to scale.
The lag between what researchers discover and what reimbursement allows has persisted for decades. Single-disease treatment programs that separate addiction care from psychiatric interventions remain common despite mounting evidence that such separation undermines outcomes. The payment model encourages fragmentation even when clinical wisdom demands integration.
The MAT Example: Evidence-Based Addiction Treatment Meets Reimbursement Reality
The tension between evidence and practice is probably most visible in substance use treatment. Research consistently shows that medication-assisted treatment (MAT), using drugs like buprenorphine or methadone alongside counseling, produces significantly better outcomes than abstinence-only approaches. The data is not ambiguous yet philosophical resistance and uneven reimbursement mean that MAT remains underutilized in settings where it could save lives. The in-network migration reshaping the SUD industry is nudging the economics of addiction treatment toward more stable reimbursement, but the shift is uneven across states and payers.
“Research tells us MAT has way more efficacy than abstinence,” Knott said. “But philosophically, if you’re not aligned with MAT treatment, your outcome measures are going to look a little bit different.”
The reimbursement landscape for MAT has somewhat improved in recent years. Medicare removed geographic restrictions for telehealth-based substance use treatment. Many states have expanded Medicaid coverage. But the patchwork of policies still creates barriers for providers trying to offer the most effective care to patients who need it most. The two-year telehealth flexibility extension for ABA and SUD providers offers some continuity, but stops short of the permanence operators say they need to build durable MAT programs.
Walking the Reimbursement Tightrope Across Behavioral Health Service Lines
Knott suggested that no provider escapes this bind, not even those who consider themselves progressive. “I think any service provider who says they’re not constrained by reimbursement is probably not looking at their entire system,” she said. “They might have a division or branch doing something experimental or new, but the reality is they’re probably not getting paid for that.”
Some payment models show us what might be possible if reimbursement aligned with evidence. Certified Community Behavioral Health Clinics (CCBHC) operate under a different structure that accounts for actual costs of care delivery, allowing clinics to include staffing needs and salary adjustments in their rates. Clinics that adopted the CCBHC model hired an average of twenty-seven new positions and saw their workforce grow by sixteen percent. When payment reflects clinical reality, providers can expand services. When it does not, they make do with what the reimbursement allows. Financial discipline matters alongside payment design, which is why a new nonprofit behavioral health financial benchmarking scorecard is drawing attention as operators try to translate aligned payment into sustainable operations.
For most behavioral health providers, the fundamental calculus has not changed. The research points in one direction while the revenue points in another. Until those vectors align, clinical practice will continue to trail behind clinical evidence, and this phrase will remain uncomfortably accurate: You do what you get paid for.
